Transforming IgA Nephropathy Care: Carlisle Companies Supports FILSPARI® as First-Line Treatment
- FILSPARI® is recommended as a first-line treatment for IgA Nephropathy in updated KDIGO guidelines.
- The PROTECT trial positions FILSPARI as a leading therapy for patients unresponsive to traditional treatments.
- CSL's collaboration with UCLOUDLINK enhances pet care through the launch of the PetPhone, integrating innovative technology.
Transforming IgA Nephropathy Care: A New Era with FILSPARI®
Recently, CSL Vifor and Travere Therapeutics, Inc. have made significant strides in the management of IgA Nephropathy (IgAN) by endorsing the updated 2025 clinical practice guidelines from the Kidney Disease: Improving Global Outcomes (KDIGO). These guidelines aim to enhance patient care by establishing clear diagnostic criteria, treatment goals, and approaches to effectively manage this kidney disease. Central to these updates is the emphasis on achieving remission of proteinuria—specifically targeting levels below 0.5 g/day, and ideally under 0.3 g/day—as well as slowing the decline of estimated glomerular filtration rate (eGFR), which are critical for improving long-term kidney health.
A notable highlight of the updated guidelines is the recommendation of FILSPARI® (sparsentan), a Dual Endothelin Angiotensin Receptor Antagonist (DEARA), as a potential first-line treatment option for IgAN. This marks a paradigm shift from the traditional Renin-Angiotensin System inhibitor (RASi)-first strategy. The clinical efficacy of FILSPARI has been demonstrated in the PROTECT trial, which enrolled more patients than all previous RASi trials combined. This positions FILSPARI as a leading contender in the treatment of IgAN-induced nephron loss, offering a promising alternative for patients who have not responded adequately to traditional therapies.
Experts in the field, such as Prof. Dr. med. Jürgen Floege from RWTH Aachen University Hospital, recognize the updated KDIGO guidelines as a significant advancement for the IgA Nephropathy community. The clarity these guidelines provide for treatment decisions is expected to improve long-term kidney outcomes for patients. Dr. Achim Obergfell, Global Medical Lead at Travere Therapeutics, underscores the inclusion of FILSPARI in these recommendations as indicative of its favorable benefit-risk profile. This recognition not only enhances the treatment landscape for IgAN but also underscores the importance of innovative therapies in providing effective, well-tolerated options for patients facing this complex disease.
In addition to the advancements in IgAN treatment, UCLOUDLINK Group Inc. has launched the PetPhone, the world's first smartphone designed for pets, through its partnership with CSL, a leading mobile service brand in Hong Kong. This innovative device integrates features such as real-time communication, health monitoring, and advanced tracking for pets, aiming to enhance pet care and connectivity. With the distribution facilitated by HKT utilizing CSL's eSIM data, the PetPhone is poised to create a new niche in the pet care market, offering pet owners enhanced safety and health insights.
Related Cashu News

Lockheed Martin Advances AI, Autonomy, and Space Exploration for Enhanced Military Operations and Safety
Lockheed Martin (Ticker: LMT) is making significant strides in integrating artificial intelligence and autonomy to enhance the efficiency and safety of military operations. The company focuses on deve…

AeroVironment Reports 133% Revenue Growth Amid Rising Military Demand for UAVs
AeroVironment (Ticker: AVAV) has emerged as a leader in the unmanned aerial vehicle (UAV) industry, particularly amidst a heightened global focus on defense technologies. The company has achieved subs…

AZZ Inc. Earnings Report Could Impact Stock Volatility and Dividend Investor Sentiment
AZZ Inc. (Ticker: AZZ) positions itself strongly in the industrial sector with its upcoming earnings report, reflecting its financial health and dividend strategy. Scheduled for release on July 8, the…

Astronics Signs Long-Term Deal with Vertical Aerospace for Valo eVTOL Power Systems
In late June 2026, Vertical Aerospace establishes a long-term agreement with Astronics Corporation (Ticker: ATRO) to supply the low-voltage power distribution system for its Valo eVTOL aircraft. This…

